Alport Syndrome Market to Grow at a Tremendous 47% CAGR Through 2036, Driven by Emerging Therapies and Expanding Clinical Pipeline | DelveInsight

The Alport syndrome market is expected to witness significant growth over the coming years, driven by advancements in genetic diagnostics, increasing disease awareness, and the introduction of targeted therapies such as ELX-02 (Exaluren) (Eloxx Pharmaceuticals), Vonafexor (Enyo Pharma),...